Alnylam Pharmaceuticals Inc ALNY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
152.33UNCH (UNCH)
Volume
18,685
Close
152.33UNCH (UNCH)
Volume
433,475
52 week range
141.98 - 218.88
Loading...
  • Open154.41
  • Day High155.41
  • Day Low151.84
  • Prev Close150.31
  • 52 Week High218.88
  • 52 Week High Date07/17/23
  • 52 Week Low141.98
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap19.184B
  • Shares Out125.93M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta0.30
  • YTD % Change-20.42

KEY STATS

  • Open154.41
  • Day High155.41
  • Day Low151.84
  • Prev Close150.31
  • 52 Week High218.88
  • 52 Week High Date07/17/23
  • 52 Week Low141.98
  • 52 Week Low Date04/25/24
  • Market Cap19.184B
  • Shares Out125.93M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta0.30
  • YTD % Change-20.42

RATIOS/PROFITABILITY

  • EPS (TTM)-2.71
  • P/E (TTM)-56.22
  • Fwd P/E (NTM)-35.86
  • EBITDA (TTM)-228.121M
  • ROE (TTM)-1,500.66%
  • Revenue (TTM)1.828B
  • Gross Margin (TTM)83.02%
  • Net Margin (TTM)-24.08%
  • Debt To Equity (MRQ)-462.63%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alnylam Pharmaceuticals Inc

 

Profile

MORE
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with...
Amy Schulman J.D.
Independent Chairman of the Board
Yvonne Greenstreet
Chief Executive Officer, Director
Jeffrey Poulton
Chief Financial Officer, Executive Vice President
Pushkal Garg M.D.
Chief Medical Officer, Executive Vice President - Development and Medical Affairs
Kevin Fitzgerald Ph.D.
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Address
675 W Kendall St
Cambridge, MA
02142-1168
United States

Top Peers

SYMBOLLASTCHG%CHG
GMAB
Genmab A/S
29.72UNCHUNCH
NBIX
Neurocrine Biosciences Inc
140.71UNCHUNCH
MEDP
Medpace Holdings Inc
392.57UNCHUNCH
SRPT
Sarepta Therapeutics Inc
133.66UNCHUNCH
EXAS
Exact Sciences Corp
62.07UNCHUNCH